Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?

2018 ◽  
pp. 37-48
Author(s):  
Ravikumar Chockalingam ◽  
Britt M. Gott ◽  
Charles R. Conway
Keyword(s):  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitors ◽  
New Look

Monoamine Oxidase Inhibitors and Weight Gain

1988 ◽  
Vol 22 (10) ◽  
pp. 755-759 ◽  
Author(s):  
Thomas G. Cantú ◽  
Joan S. Korek
Keyword(s):  
Weight Gain ◽  
Literature Review ◽  
Monoamine Oxidase ◽  
Tricyclic Antidepressants ◽  
Monoamine Oxidase Inhibitors ◽  
Weight Changes ◽  
Appetite Control ◽  
Drug Induced ◽  
Relative Potential ◽  
Induce Weight Gain

Weight gain associated with antidepressant therapy is a common problem that often results in noncompliance. Some authors suggest that monoamine oxidase inhibitors (MAOI) are less likely to produce weight gain than tricyclic antidepressants. This paper addresses the relative potential for weight gain with the MAOI. Assessing the potential for antidepressant-induced weight gain necessitates separating the weight changes associated with alterations in mood disorders from those due to drug-induced alterations in appetite control. The mechanisms of appetite control are reviewed briefly followed by proposed mechanisms by which the MAOI may alter this control. A literature review suggests that phenelzine is the MAOI most likely to induce weight gain; reports of isocarboxazid-induced weight gain are less common. There are no cases of tranylcypromine-induced weight gain in the literature that are clearly associated with the drug. The MAOI probably have different effects on the mechanisms of appetite control.

Management of Depression, Part 2: Treatment Options

2018 ◽  
Author(s):  
Michael Banov
Keyword(s):  
Monoamine Oxidase ◽  
Mental Health Professionals ◽  
Serotonin Reuptake ◽  
Tricyclic Antidepressants ◽  
Antidepressant Medication ◽  
Monoamine Oxidase Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Clinical Depression ◽  
Depression Treatment ◽  
Norepinephrine Reuptake

Clinical depression is a commonly occurring and profoundly disabling condition that affects approximately 4%, or nearly 350 million people, worldwide according to the World Health Organization. Managing depression is challenging due to the marked variability in biological contributors, the heterogeneity of the illness, psychosocial history, current stresses exacerbating the condition, medical and psychiatric co-occurring conditions, lifestyle, and motivation and willingness to accept and engage in treatment recommendations. Mental health professionals such as master-level counselors, psychologists, or psychiatrists are specially trained to identify and treat depression; however, a significant amount of depression presents in primary care medical settings. This review covers treatment of depression with psychotherapy, complementary and alternative medicine (CAM), and antidepressant medication, as well as treatment course and long-term depression treatment. Tables list CAM depression treatments, nonnutraceutical CAM therapies, managing antidepressant side effects, tricyclic antidepressants, serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine dopamine reuptake inhibitor, alpha2 antagonists, serotonin-2 antagonist/reuptake inhibitors, monoamine oxidase inhibitors, food restrictions with monoamine oxidase inhibitors, managing partial response/treatment-resistant depression, and serotonin receptor modulators.   This review contains 15 tables and 98 references Key words: antidepressant medication, clinical depression, depression, monoamine oxidase inhibitors, nonpharmacologic depression treatment, omega-3 fatty acids, S-adenosylmethionine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, St. John’s wort, tricyclic antidepressants

Sign in / Sign up

Export Citation Format

Share Document